BioSpace News Archive

Almirall will have exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828 in several fields, including immune inflammatory dermatological indications.

The regulator’s approval means AstraZeneca’s Tagrisso can now be used in combination with chemotherapy for locally advanced or metastatic EGFR-mutated non-small cell lung cancer patients.

The companies’ Biologics License Application for antibody-drug conjugate datopotamab deruxtecan has been accepted by the FDA for locally advanced or metastatic nonsquamous non-small cell lung cancer.

In a Phase II study, Sanofi and Denali’s RIPK1 inhibitor SAR443820/DNL788 failed to meet the primary endpoint of improved functional performance in amyotrophic lateral sclerosis patients.

Certa Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis, having previously granted Orphan Drug Designation.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO ® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older.

Biotricity Inc. announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024.

Single Pass, with the first and only biopsy closure cauterization device, is delighted to announce the successful completion of the first real- life cases utilizing the groundbreaking device.

AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn’s and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

Southwest Research Institute’s advisory trustees, board of directors and special guests gathered at the SwRI campus in San Antonio for the Institute’s 76th Annual Meeting.